(HealthDay News) – Finasteride is associated with a reduction in the risk of prostate cancer, but is not associated with improved survival over 18 years, according to a study published in the Aug. 15 issue of the New England Journal of Medicine.
Ian M. Thompson Jr., MD, from the University of Texas Health Science Center at San Antonio, and colleagues analyzed survival rates among all participants from the Prostate Cancer Prevention Trial through Oct. 31, 2011.
Of the 18,880 eligible men who underwent randomization in the trial, the researchers found that prostate cancer was diagnosed in 10.5% of men in the finasteride group and 14.9% of men in the placebo group (relative risk, 0.7; P<0.001). High-grade disease was detected in 3.5% of the men in the finasteride group vs. 3% of men in the placebo group (relative risk, 1.17; P=0.05). The 15-year survival rates were 78% for the finasteride group and 78.2% for the placebo group (unadjusted hazard ratio for death, 1.02; P=0.46). For those with low-grade prostate cancer, the 10-year survival rates were 83% in the finasteride group and 80.9% in the placebo group, while the 10-year survival rates were 73% and 73.6%, respectively, for those with high-grade disease.
“Data from 18 years of follow-up showed that the use of finasteride over a period of seven years in a general population of men with a median age at study entry of 63.2 years reduced the risk of prostate cancer but did not significantly affect mortality,” the authors write.
Two authors disclosed financial ties to the pharmaceutical industry; one author is a named inventor on patent applications, including one for identification of biomarkers for prostate cancer detection.